Pediatr. praxi. 2008;9(5):315-318

THE SIGNIFICANCE OF ROTAVIRAL INFECTION, POSSIBILITIES OF THE VACCINATION

doc. MUDr. Petr Pazdiora CSc
Ústav epidemiologie LF UK, Plzeň

Rotaviruses cause annually 111–125 million of illnesses leading to 0.5–1 million of deaths worldwide. As many as 3,028 sporadic cases and 458 cases from 18 outbreaks were reported to the Public Health Service in 2007 in the Czech Republic. No case was lethal. In 2007 4,571 rotavirus infection were laboratory confirmed in 83 laboratories of the Czech Republic. Specific morbidity among children under 3 years calculated on the laboratory data was 717.9 cases/100,000 population/year; among children under 5 years it was 594.1/100,000.

With registration of 2 new vaccines (Rotarix, RotaTeq) it is realistic to gradually fulfil extended WHO immunisation programme that intends to introduce vaccinations against these infections. Both vaccines despite different properties confirm a high level of imunogenicity and protection. They are gradually introduced to the market not only in the European countries but also in other countries. Numbers of immunised children are till very low in the Czech Republic.

Keywords: Key words: Rotarix, RotaTeq, rotavirus infection, vaccination, Czech Republic.

Published: November 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pazdiora P. THE SIGNIFICANCE OF ROTAVIRAL INFECTION, POSSIBILITIES OF THE VACCINATION. Pediatr. praxi. 2008;9(5):315-318.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ambrožová H, Schramlová J. Virové gastroenteritidy u dětí. Klin Mikrobiol Inf Lek 2005; 11: 83-91.
    2. Berner R, Schumacher RF, Hameister S, et al. Occurrence and impact of community-acquired and nosocomial rotavirus infections - a hospital-based study over 10 y. A. Paediatr 1999; 88: 48-52. Go to original source... Go to PubMed...
    3. CDC: Delayed onset and diminished magnitude of rotavirus activity - United States, November 2007 - May 2008. MMWR 2008; 57: 697-700. Go to PubMed...
    4. Giaquinto C, Van Damme P, Huet F, et al. Clinical consequences of rotavirus acute gastroenteritis in Europe, 2004-2005: the REVEAL study. J Infect Dis 2007; 195: 26-35. Go to original source... Go to PubMed...
    5. Goveia MG, DiNubile MJ, Dallas MJ, et al. Efficacy of pentavalent human-bovine (WC3) reassortant rotavirus vaccine based on breastfeeding frequency. Pediatr Infect Dis J 2008; 27: 656-658. Go to original source... Go to PubMed...
    6. Haber P, Patel M, Izurieta HS, et al. Postlicensure monitoring of intussusception after RotaTeq vaccination in the United States, February 1, 2006, to September 25, 2007. Pediatrics 2008; 121: 1206-1212. Go to original source... Go to PubMed...
    7. Meyer N, Diez-Domingo J, Baldo JM, et al. Establishing primary care based surveillance to estimate the burden of rotavirus gastroenteritis in children aged < 5 years in Europe. 5th World congress of the World society for pediatric infectious diseases (WSPID) 2007; Bangkok, Thailand, November 15-18.
    8. Orenstein WA, Hadler S, Kuritsky JN, et al. Rotavirus vaccines-from licensure to disease reduction. J Infect Dis 1996; 174: 118-124. Go to original source... Go to PubMed...
    9. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003; 9: 565-572. Go to original source... Go to PubMed...
    10. Pazdiora P. Diagnostika rotavirových infekcí v r. 2004, jejich základní charakteristiky v letech 1998-2004 v ČR. Epidem Mikrobiol Imunol 2006; 55: 32-36.
    11. Rendi-Wagner P, Kundi M, Mikolasek A, et al. Active hospital-based surveillance of rotavirus diarrhea in Austrian children, period 1997 to 2003. Wien Klin Wochenschr 2006; 118: 280-285. Go to original source... Go to PubMed...
    12. Rheingans RD, Heylen J, Giaquinto C. Economics of rotavirus gastroenteritis and vaccination in Europe: what makes sense? Pediatr Infect Dis J 2006; 25: 48-55. Go to original source... Go to PubMed...
    13. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354: 11-22. Go to original source... Go to PubMed...
    14. Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication fot the development and implementation of an effective rotavirus vaccine. Rev Med Virol 2005; 15: 26-56. Go to original source... Go to PubMed...
    15. Soriano-Gabarró M, Mrukowicz J, Vesikari T, Verstraeten T. Burden of rotavirus disease in Europe: time for effective prevention? Pediatr Infect Dis J 2006; 25: 7-11. Go to original source... Go to PubMed...
    16. Souhrn SPC. EU/1/05/330/001/004. Souhrn údajů o přípravku ROTARIX. Datum revize textu 19. 6. 2008.
    17. Souhrn SPC. EU/1/06/338/001-002. Souhrn údajů o přípravku ROTATEQ. Datum revize textu 23. 4. 2008.
    18. Táborská J, Pazdiora P. Rotavirus jako nejčastější původce průjmů u dětí. Pediatr. pro Praxi 2005; 6: 135-140.
    19. Van Damme P, Van der Wielen M, Ansaldi F, et al. Rotavirus vaccines: considerations for successful implementation in Europe. Lancet Infect Dis 2006; 6: 805-812. Go to original source... Go to PubMed...
    20. Vesikari T, Joensuu J, Baer M, et al. Concurrent administration of rhesus rotavirus tetravalent (RRV-TV) vaccine with pentavalent diphteria-pertussis-tetanus-Haemophilus influenzae betainactivated polio and hepatitis B vaccines. A Paediatr 1999; 88: 513-520. Go to original source... Go to PubMed...
    21. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006; 354: 23-33. Go to original source... Go to PubMed...
    22. Vesikari T, Karvonen A, Ferrante SA, et al. Efficacy of the pentavalent rotavirus vaccine, RotaTeq(TM), against hospitalisations and emergency department visits up to 3 years postvaccination: the Finnish extension study. 13th International Congress on Infectious Diseases, 2008; Kuala Lumpur, Malaysia, June 19-22. Go to original source...
    23. Vesikari T, Van Damme P, Giaquinto C, et al. European Society for Paediatric Infectious Diseases/European Society for Paediatric Gastroenterology, Hepatology, and Nutrition evidencebased recommendations for rotavirus vaccination in Europe. J Pediatr Gastroenterol Nutr 2008; Suppl 2: 38-48. Go to original source... Go to PubMed...
    24. Watson B. Vaccines in the pipeline-an overview. Infect Med 2001; 18: 27-32.

    Return to the content


    Pediatrics for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.